Stories about Heart arrhythmia

Subscribe to topic

Subscribe to Heart arrhythmia

17.12.2019 – 14:24
Personal MedSystems GmbH
2
App-based ECG CardioSecur Now Available in South America
more
How it works
One document
19.11.2019 – 11:18
Personal MedSystems GmbH
2
CardioSecur introduces 3D-ECG for virtual trials at Clinical Trials Europe
more
mHealth Powered Virtual Trials
One document
12.10.2019 – 10:45
Daiichi Sankyo
European Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA® (edoxaban)
Munich (ots/PRNewswire) - - One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV events in elderly NVAF patients1 - The Global ETNA-AF programme is currently the largest and most comprehensive ...
more
04.09.2019 – 08:01
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA® (edoxaban) in Patients with Atrial Fibrillation
Munich (ots/PRNewswire) - - ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - Data ...
more
02.09.2019 – 14:00
Daiichi Sankyo Europe GmbH
ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF Patients
Munich (ots/PRNewswire) - - Global and European real-world outcome analyses in non-selected atrial fibrillation (AF) patients on edoxaban, including those who are elderly with comorbidities, were reported at ESC Congress 2019 - At present, the Global ETNA-AF programme is the largest and most comprehensive repository ...
more
22.08.2019 – 09:00
Daiichi Sankyo
Daiichi Sankyo Announces the Presentation of New Data on LIXIANA® (edoxaban) to be Presented at ESC Congress 2019
Munich (ots/PRNewswire) - - Data presentations from ENTRUST-AF PCI and ETNA-AF add to the growing body of scientific evidence from the Edoxaban Clinical Research Programme - First-time presentation of ENTRUST-AF PCI clincial results assessing edoxaban in atrial fibrillation (AF) patients following a successful ...
more
24.07.2019 – 10:48
Technische Universität München
Atrial fibrillation: New marker for atrial damage discovered
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 23325 - email: presse@tum.de - web: www.tum.de This text on the web: http://www.tum.de/nc/en/about-tum/news/press-releases/details/35595/ High resolution image: https://mediatum.ub.tum.de/1515114 NEWS RELEASE New marker for atrial damage discovered Protein in blood provides better control of treatment for atrial fibrillation Atrial ...
more
19.03.2019 – 10:30
Daiichi Sankyo Europe GmbH
Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA® Undergoing Diagnostic or Therapeutic Procedures
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...
more
18.03.2019 – 15:00
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA® (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...
more
11.10.2018 – 14:08
Personal MedSystems GmbH
Heart Attack more lethal than Arrhythmia - What Apple Watch covers
more
More about CardioSecur
11.09.2018 – 14:31
Merck KGaA
BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
more
28.08.2018 – 16:39
Thrombosis Research Institute
Real-world Evidence From GARFIELD-AF Shows Superior Reduction in Mortality With Non-vitamin K Antagonists Oral Anticoagulants (NOACs) vs. Vitamin K Antagonists (VKAs) in Newly Diagnosed Atrial Fibrillation
Munich (ots/PRNewswire) - - High-risk patients on anticoagulants (AC) for stroke prevention also have 17% fewer deaths over 2 years of follow-up than patients who are not treated with AC - Patients who receive AC plus add-on antiplatelet therapy (AP) for stroke prevention have a significantly worse prognosis than ...
more
20.08.2018 – 16:00
The Thrombosis Research Institute
Thrombosis Research Institute (TRI) to Announce New Real-World Insights in Atrial Fibrillation at ESC Congress 2018
Munich (ots/PRNewswire) - - Satellite symposium will highlight the breadth of evidence collected since the establishment of the registry in 2009 - An analysis of the comparative effectiveness of oral anticoagulants in everyday practice will be presented - The economic burden of atrial fibrillation (AF) in nine ...
more

1